FPA 144

Drug Profile

FPA 144

Alternative Names: FPA144

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Jul 2016 FPA 144 receives Orphan Drug status for Gastric cancer in USA
  • 06 Jun 2016 Efficacy and Adverse events data from a phase I trial in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 18 Apr 2016 New pharmacodynamics data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research(AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top